Julie K. Jadlowsky

Julie K. Jadlowsky

Auto-generated profile, based on publicly available information

Julie K. Jadlowsky

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SBStephen Joseph Bagley
Stephen Joseph Bagley
MLMeghan Logun
Meghan Logun
JFJoseph A. Fraietta
Joseph A. Fraietta
XWXin Wang
Xin Wang
ADArati S. Desai
Arati S. Desai
DODonald M. O’rourke
Donald M. O’rourke

1 June 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SBStephen Joseph Bagley
Stephen Joseph Bagley
ADArati S. Desai
Arati S. Desai
JFJoseph A. Fraietta
Joseph A. Fraietta
DSDana Silverbush
Dana Silverbush
DCDaniel Chafamo
Daniel Chafamo
DODonald M. O’rOurke
Donald M. O’rOurke

20 January 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JJJulie K. Jadlowsky
Julie K. Jadlowsky
EHElizabeth O. Hexner
Elizabeth O. Hexner
AMAmy Marshall
Amy Marshall
SGStephan A. Grupp
Stephan A. Grupp
NFNoelle V. Frey
Noelle V. Frey
JFJoseph A. Fraietta
Joseph A. Fraietta

1 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
PTPablo Tebas
Pablo Tebas
JJJulie K. Jadlowsky
Julie K. Jadlowsky
PSPamela A. Shaw
Pamela A. Shaw
LTLifeng Tian
Lifeng Tian
EEErin Esparza
Erin Esparza
JRJames L. Riley
James L. Riley
Background. We conducted a phase I clinical trial that infused CCR5 gene–edited CD4+ T cells to determine how these T cells can better enable HIV cure strategies. Methods. The aim of trial was to develop RNA-based approaches to deliver zinc finger nuclease (ZFN), evaluate the effect of CCR5 gene–edited CD4+ T cells on the HIV-specific T cell response, test the ability of infused CCR5 gene–edited T cells to delay viral rebound during analytical treatment interruption, and determine whether individuals heterozygous for CCR5 Δ32 preferentially benefit. We enrolled 14 individuals living with HIV whose viral load was well controlled by antiretroviral therapy (ART). We measured the time to viral rebound after ART withdrawal, the persistence of CCR5-edited CD4+ T cells, and whether infusion of 10 billion CCR5-edited CD4+ T cells augmented the HIV-specific immune response. Results. Infusion of the CD4+ T cells was well tolerated, with no serious adverse events. We observed a modest delay in the time to viral rebound relative to historical controls; however, 3 of the 14 individuals, 2 of whom were heterozygous for CCR5 Δ32, showed post-viral rebound control of viremia, before ultimately losing control of viral replication. Interestingly, only these individuals had substantial restoration of HIV-specific CD8+ T cell responses. We observed immune escape for 1 of these reinvigorated responses at viral recrudescence, illustrating a direct link between viral control and enhanced CD8+ T cell responses. Conclusion. These findings demonstrate how CCR5 gene–edited CD4+ T cell infusion could aid HIV cure strategies by augmenting preexisting HIV-specific immune responses. REGISTRATION. ClinicalTrials.gov NCT02388594. Funding. NIH funding (R01AI104400, UM1AI126620, U19AI149680, T32AI007632) was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS). Sangamo Therapeutics also provided funding for these studies.

15 November 2024 in Science Advances
Verified
Journal Article
Open access
ADAlexander J. Dimitri
Alexander J. Dimitri
ABAmy E. Baxter
Amy E. Baxter
GCGregory M. Chen
Gregory M. Chen
CHCaitlin R. Hopkins
Caitlin R. Hopkins
GRGeoffrey T. Rouin
Geoffrey T. Rouin
JFJoseph A. Fraietta
Joseph A. Fraietta
CD8 + T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting TET2 in CAR T cells provides therapeutic benefit; however, TET2’s role in exhausted T cell (T EX ) development is unclear. In chronic lymphocytic choriomeningitis virus (LCMV) infection, TET2 drove conversion from stem cell–like T EX progenitors toward terminally differentiated and effector (T EFF )–like T EX . TET2 also enforced a terminally differentiated state in the early bifurcation between T EFF and T EX , indicating broad roles for TET2 in acquisition of effector biology. To exploit the therapeutic potential of TET2, we developed clinically actionable TET2- targeted CAR T cells by disrupting TET2 via knock-in of a safety switch alongside CAR knock-in at the TRAC locus. TET2 -targeted CAR T cells exhibited restrained terminal exhaustion in vitro and enhanced antitumor responses in vivo. Thus, TET2 regulates fate transitions in T EX differentiation and can be targeted with a safety mechanism in CAR T cells for improved tumor control.

10 January 2024 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JJJulie K. Jadlowsky
Julie K. Jadlowsky
RLRachel Leskowitz
Rachel Leskowitz
SMStephen McKenna
Stephen McKenna
JKJayashree Karar
Jayashree Karar
YMYujie Ma
Yujie Ma
CJCarl H. June
Carl H. June
The use of lentiviral vectors in cell and gene therapy is steadily increasing, both in commercial and investigational therapies. Although existing data increasingly support the usefulness and safety of clinical-grade lentiviral vectors used in cell manufacturing, comprehensive studies specifically addressing their long-term stability are currently lacking. This is significant considering the high cost of producing and testing GMP-grade vectors, the limited number of production facilities, and lengthy queue for production slots. Therefore, an extended shelf life is a critical attribute to justify the investment in large vector lots for investigational cell therapies. This study offers a thorough examination of essential stability attributes, including vector titer, transduction efficiency, and potency for a series of clinical-grade vector lots, each assessed at a minimum of 36 months following their date of manufacture. The 13 vector lots included in this study were used for cell product manufacturing in 16 different clinical trials, and at the time of the analysis had a maximum storage time at −80°C of up to 8 years. The results emphasize the long-term durability and efficacy of GMP-grade lentiviral vectors for use in ex vivo cell therapy manufacturing.